Pharmacological treatment options for cryopyrin-associated periodic syndromes

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study

(2017) Karoline Krause et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

(2017) Veronika K. Jaeger et al.   RHEUMATOLOGY

Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial

(2017) Ilan Ben-Zvi et al.   Arthritis & Rheumatology

Bridging the Gap between the Clinician and the Patient with Cryopyrin-Associated Periodic Syndromes

(2017) L. Cantarini et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)

(2016) Jasmin B Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial)

(2016) Adriana H. Tremoulet et al.   Contemporary Clinical Trials

Anakinra

(2016) George Lazaros et al.   Journal of Cardiovascular Medicine

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus

(2016) Elizabeth A. McKie et al.   PLoS One

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

(2016) Torbjörn Kullenberg et al.   RHEUMATOLOGY

Brief Report: Severe Inflammation Following Vaccination AgainstStreptococcus pneumoniaein Patients With Cryopyrin-Associated Periodic Syndromes

(2016) Ulrich A. Walker et al.   Arthritis & Rheumatology

Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)

(2015) Antonio Abbate et al.   AMERICAN JOURNAL OF CARDIOLOGY

Recommendations for the management of autoinflammatory diseases

(2015) Nienke M ter Haar et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab

(2015) B. Mansouri et al.   BRITISH JOURNAL OF DERMATOLOGY

One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

(2015) Edwin J.P. van Asseldonk et al.   CLINICAL IMMUNOLOGY

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

(2015) Giacomo Emmi et al.   CLINICAL RHEUMATOLOGY

The PYRIN Domain-only Protein POP1 Inhibits Inflammasome Assembly and Ameliorates Inflammatory Disease

(2015) Lucia de Almeida et al.   IMMUNITY

The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β

(2015) Jean-Michel Rondeau et al.   mAbs

International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors

(2015) T Youngstein et al.   Pediatric Rheumatology

Canakinumab for the treatment of chronic obstructive pulmonary disease

(2015) Paola Rogliani et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome

(2015) Jasmin B. Kuemmerle-Deschner et al.   RHEUMATOLOGY

Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study

(2015) Laetitia Houx et al.   Arthritis & Rheumatology

Brief Report: Cryopyrin-Associated Periodic Syndrome Caused by a Myeloid-Restricted SomaticNLRP3Mutation

(2015) Qing Zhou et al.   Arthritis & Rheumatology

A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

(2014) Cailin H Sibley et al.   ANNALS OF THE RHEUMATIC DISEASES

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry

(2014) R Levy et al.   ANNALS OF THE RHEUMATIC DISEASES

Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS)

(2014) M. H. Haverkamp et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study

(2014) J. S. Sundy et al.   JOURNAL OF RHEUMATOLOGY

A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy

(2014) Angeline XH Goh et al.   mAbs

The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

(2014) Philip J. Hashkes et al.   Biomed Research International

Brief Report: Anakinra Use During Pregnancy in Patients With Cryopyrin-Associated Periodic Syndromes

(2014) Zenas Chang et al.   Arthritis & Rheumatology

Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

(2014) Norman T. Ilowite et al.   Arthritis & Rheumatology

SomaticNLRP3mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes

(2013) Kenji Nakagawa et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra treatment in drug-resistant Behcet’s disease: a case series

(2013) Luca Cantarini et al.   CLINICAL RHEUMATOLOGY

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

(2013) J. Hensen et al.   DIABETES & METABOLISM

Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies

(2013) Susannah D. Brydges et al.   JOURNAL OF CLINICAL INVESTIGATION

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications

(2013) L. S. Snegireva et al.   RHEUMATOLOGY

Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience

(2013) R. A. G. Russo et al.   RHEUMATOLOGY

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

(2013) Jasmin B Kuemmerle-Deschner et al.   ARTHRITIS RESEARCH & THERAPY

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

(2013) Roberta Caorsi et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

(2013) Sébastien Ottaviani et al.   ARTHRITIS RESEARCH & THERAPY

Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians

(2013) Jasmin B. Kuemmerle-Deschner et al.   Therapeutic Advances in Musculoskeletal Disease

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

(2012) K. Krause et al.   ALLERGY

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

(2012) Nienke ter Haar et al.   ANNALS OF THE RHEUMATIC DISEASES

Inflammasomes and Their Roles in Health and Disease

(2012) Mohamed Lamkanfi et al.   Annual Review of Cell and Developmental Biology

Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes

(2012) Cailin H. Sibley et al.   ARTHRITIS AND RHEUMATISM

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

(2012) Paul M Ridker et al.   CIRCULATION

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

(2012) Abhijit Chakraborty et al.   CLINICAL PHARMACOKINETICS

Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study

(2012) Hal M. Hoffman et al.   CLINICAL THERAPEUTICS

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

(2012) C. Cavelti-Weder et al.   DIABETES CARE

Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature

(2012) Sébastien Ottaviani et al.   JOINT BONE SPINE

One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

(2012) Michaela Blech et al.   JOURNAL OF MOLECULAR BIOLOGY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

(2011) J. B. Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study

(2011) Naoko Tanaka et al.   ARTHRITIS AND RHEUMATISM

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

(2011) C. A. Dinarello   BLOOD

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

(2011) Alexander M. Owyang et al.   mAbs

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

(2011) Jasmin B Kuemmerle-Deschner et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study

(2011) Katerina Laskari et al.   ARTHRITIS RESEARCH & THERAPY

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

(2011) Isabelle Koné-Paut et al.   ARTHRITIS RESEARCH & THERAPY

Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France

(2010) L. Cuisset et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome

(2010) Jasmin B. Kuemmerle-Deschner et al.   ARTHRITIS AND RHEUMATISM

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

(2010) Marina K. Roell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates

(2010) Elizabeth Fox et al.   JOURNAL OF NEUROIMMUNOLOGY

Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra

(2010) Loredana Lepore et al.   JOURNAL OF PEDIATRICS

Effect of anakinra on arthropathy in CINCA/NOMID syndrome

(2010) Takako Miyamae et al.   Pediatric Rheumatology

Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1  secretion

(2010) S. Tassi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease

(2009) Seth L. Masters et al.   Annual Review of Immunology

The Inflammasomes: Guardians of the Body

(2009) Fabio Martinon et al.   Annual Review of Immunology

Immunological and Inflammatory Functions of the Interleukin-1 Family

(2009) Charles A. Dinarello   Annual Review of Immunology

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

(2009) Bénédicte Neven et al.   ARTHRITIS AND RHEUMATISM

Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)

(2009) Hal M Hoffman   EXPERT OPINION ON BIOLOGICAL THERAPY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome

(2008) Raphaela Goldbach-Mansky et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity

(2008) Hal M. Hoffman et al.   CURRENT MEDICAL RESEARCH AND OPINION

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

(2008) Rieke Alten et al.   ARTHRITIS RESEARCH & THERAPY

Cryopyrinopathies: update on pathogenesis and treatment

(2008) Bénédicte Neven et al.   Nature clinical practice. Rheumatology